You are here

ChromaDex Chairman Stephen Allen Will Retire from Board of Directors

IRVINE, Calif., Feb. 16, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to pioneering technologies that improve the way people age is announcing that on February 13, 2018, Steve R. Allen, the Chairman of the Board, informed the Company that he intends to retire from the Board of Directors at the end of his current term after four years of service.  Accordingly, Mr. Allen will not stand for re-election as a director at ChromaDex’s 2018 Annual Meeting in June.

Steve Allen, Chairman of the Board commented, “Over the past four years, I have had the distinct honor to serve on the board of ChromaDex.  I am very proud of our Company’s accomplishments in making TRU NIAGEN®, a global brand.  I wish the entire ChromaDex team continued success as the Company continues to evolve and execute on its plan and create long-term value for its shareholders.”

Frank Jaksch, CEO and Co-founder of ChromaDex said, “On behalf of the board and everyone at ChromaDex, I would like to thank Steve for his leadership as Chairman, and also for his dedication and commitment to ChromaDex.  His insights and wisdom around our strategy will certainly be missed."

Rob Fried, President and Chief Operating Officer,  said, “Many of us joined this Company in part because of Steve Allen.  We wish only the best to Steve and his family.”

About ChromaDex:

ChromaDex Corp. is an integrated, global nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to uncover the full potential of NAD and identify and develop novel, science-based ingredients. Its flagship ingredient, NIAGEN® nicotinamide riboside, sold directly to consumers as TRU NIAGEN®, is backed with clinical and scientific research, as well as extensive IP protection. TRU NIAGEN® is helping the world AGE BETTER®. To learn more about ChromaDex, please visit www.ChromaDex.com.

Forward-Looking Statements:

This release contains forward-looking statements relating to ChromaDex and ChromaDex’s business within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to ChromaDex executing its future plan and creating long-term value for its shareholders. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Investor Relations Contact:

Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com

ChromaDex Public Relations Contact:

Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com

Friday, February 16, 2018 - 16:30

More Headlines

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
Patients with MS Suffered Stroke, Blood Vessel Tearing in Head and Neck After Receiving Drug
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
Life-Threatening Side Effect of Drug for Acute Myeloid Leukemia
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
Gene Therapy Granted Regenerative Medicine, Fast Track Designations